These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
50. Challenges relating to the therapeutic management of neuropathic pain. Alcántara Montero A; González Curado A Rev Esp Anestesiol Reanim (Engl Ed); 2019 Oct; 66(8):452-453. PubMed ID: 31153594 [No Abstract] [Full Text] [Related]
51. The plasticity of the association between mu-opioid receptor and glutamate ionotropic receptor N in opioid analgesic tolerance and neuropathic pain. Sánchez-Blázquez P; Rodríguez-Muñoz M; Berrocoso E; Garzón J Eur J Pharmacol; 2013 Sep; 716(1-3):94-105. PubMed ID: 23499699 [TBL] [Abstract][Full Text] [Related]
52. Research progress of mechanisms and drug therapy for neuropathic pain. Yan YY; Li CY; Zhou L; Ao LY; Fang WR; Li YM Life Sci; 2017 Dec; 190():68-77. PubMed ID: 28964813 [TBL] [Abstract][Full Text] [Related]
53. Computer-Aided Drug Discovery (CADD) Approaches for the Management of Neuropathic Pain. Ramesh M; Muthuraman A Curr Top Med Chem; 2021; 21(32):2856-2868. PubMed ID: 34809547 [TBL] [Abstract][Full Text] [Related]
54. The endocannabinoid system and neuropathic pain. Maldonado R; Baños JE; Cabañero D Pain; 2016 Feb; 157 Suppl 1():S23-S32. PubMed ID: 26785153 [TBL] [Abstract][Full Text] [Related]
55. Targeting cannabinoid agonists for inflammatory and neuropathic pain. Cheng Y; Hitchcock SA Expert Opin Investig Drugs; 2007 Jul; 16(7):951-65. PubMed ID: 17594182 [TBL] [Abstract][Full Text] [Related]
56. Challenges in the development of novel treatment strategies for neuropathic pain. Ossipov MH; Porreca F NeuroRx; 2005 Oct; 2(4):650-61. PubMed ID: 16489372 [TBL] [Abstract][Full Text] [Related]
57. Strategies for measuring non-evoked pain in preclinical models of neuropathic pain: Systematic review. Huerta MÁ; Cisneros E; Alique M; Roza C Neurosci Biobehav Rev; 2024 Aug; 163():105761. PubMed ID: 38852847 [TBL] [Abstract][Full Text] [Related]
58. Microinjection of histamine and its H Salimi S; Tamaddonfard E Eur J Pharmacol; 2019 Aug; 857():172450. PubMed ID: 31202805 [TBL] [Abstract][Full Text] [Related]
59. Central and peripheral sites of action for CB₂ receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Hsieh GC; Pai M; Chandran P; Hooker BA; Zhu CZ; Salyers AK; Wensink EJ; Zhan C; Carroll WA; Dart MJ; Yao BB; Honore P; Meyer MD Br J Pharmacol; 2011 Jan; 162(2):428-40. PubMed ID: 20880025 [TBL] [Abstract][Full Text] [Related]
60. Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief. Moriconi A; Cunha TM; Souza GR; Lopes AH; Cunha FQ; Carneiro VL; Pinto LG; Brandolini L; Aramini A; Bizzarri C; Bianchini G; Beccari AR; Fanton M; Bruno A; Costantino G; Bertini R; Galliera E; Locati M; Ferreira SH; Teixeira MM; Allegretti M Proc Natl Acad Sci U S A; 2014 Nov; 111(47):16937-42. PubMed ID: 25385614 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]